Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Socrates E Papapoulos

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 13, 2012
Low-energy fractures of the humeral shaft and bisphosphonate useMaria P Yavropoulou, Andrea Giusti, Sharita R Ramautar, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 8, 2009
Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragilityMatthijs P Somford, Frits W Draijer, Bregje J W Thomassen, et al.
JBMR Plus|March 17, 2025
Long-term clinical and bone mineral density changes of adult patients with sclerostin deficiency due to van Buchem disease: a follow-up studyNatasha M Appelman-Dijkstra, Telli Merve Avci, Manuela Schoeb, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 2, 2023
The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injectionPolyzois Makras, Maria P Yavropoulou, Stergios A Polyzos, et al.
European Journal of Endocrinology|March 12, 2017
Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatmentAthanasios D Anastasilakis, Maria P Yavropoulou, Polyzois Makras, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 18, 2012
Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriersAntoon H van Lierop, Neveen A T Hamdy, Martje E van Egmond, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 26, 2011
Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnoverAntoon H van Lierop, Neveen At Hamdy, Herman Hamersma, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 27, 2005
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formationKenneth E S Poole, Rutger L van Bezooijen, Nigel Loveridge, et al.
The Journal of Clinical Endocrinology and Metabolism|August 8, 2019
Denosumab in Patients With Fibrous Dysplasia Previously Treated With BisphosphonatesBas C J Majoor, Socrates E Papapoulos, P D Sander Dijkstra, et al.
Current Medical Research and Opinion|August 17, 2019
Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trialJohn P Bilezikian, Gary Hattersley, Bruce H Mitlak, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 13, 2012
Low-energy fractures of the humeral shaft and bisphosphonate useMaria P Yavropoulou, Andrea Giusti, Sharita R Ramautar, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 8, 2009
Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragilityMatthijs P Somford, Frits W Draijer, Bregje J W Thomassen, et al.
JBMR Plus|March 17, 2025
Long-term clinical and bone mineral density changes of adult patients with sclerostin deficiency due to van Buchem disease: a follow-up studyNatasha M Appelman-Dijkstra, Telli Merve Avci, Manuela Schoeb, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 2, 2023
The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injectionPolyzois Makras, Maria P Yavropoulou, Stergios A Polyzos, et al.
European Journal of Endocrinology|March 12, 2017
Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatmentAthanasios D Anastasilakis, Maria P Yavropoulou, Polyzois Makras, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 18, 2012
Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriersAntoon H van Lierop, Neveen A T Hamdy, Martje E van Egmond, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 26, 2011
Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnoverAntoon H van Lierop, Neveen At Hamdy, Herman Hamersma, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 27, 2005
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formationKenneth E S Poole, Rutger L van Bezooijen, Nigel Loveridge, et al.
The Journal of Clinical Endocrinology and Metabolism|August 8, 2019
Denosumab in Patients With Fibrous Dysplasia Previously Treated With BisphosphonatesBas C J Majoor, Socrates E Papapoulos, P D Sander Dijkstra, et al.
Current Medical Research and Opinion|August 17, 2019
Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trialJohn P Bilezikian, Gary Hattersley, Bruce H Mitlak, et al.
Pageof 8